[Federal Register Volume 60, Number 128 (Wednesday, July 5, 1995)]
[Notices]
[Pages 35050-35052]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-16321]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA No. 132F]
1995 Revised Aggregate Production Quotas for Controlled
Substances in Schedules I and II
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of final revised aggregate production quotas for 1995.
-----------------------------------------------------------------------
SUMMARY: This notice establishes revised 1995 aggregate production
quotas for controlled substances in Schedules I and II of the
Controlled Substances Act (CSA).
DATES: This order is effective on July 5, 1995.
FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief, Drug and
Chemical Evaluation Section, Drug Enforcement Administration,
Washington, D.C. 20537, Telephone: (202) 307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826)
requires the Attorney General to establish aggregate production quotas
for controlled substances in Schedules I and II each year. This
responsibility has been delegated to the Administrator of the DEA
pursuant to Section 0.100 of Title 28 of the Code of Federal
Regulations. The Administrator, in turn, has redelegated this function
to the Deputy Administrator of the DEA pursuant to Section 0.104 of
Title 28 of the Code of Federal Regulations.
On May 9, 1995, a notice of the proposed revised 1995 aggregate
production quotas for controlled substances in Schedules I and II was
published in the Federal Register (60 FR 24649). All interested parties
were invited to comment on or object to these proposed aggregate
production quotas on or before June 9, 1995.
Several companies commented that the revised 1995 aggregate
production quotas for amphetamine, diphenoxylate, fentanyl,
hydrocodone, hydromorphone, methadone, methadone intermediate (for
conversion), methylphenidate, morphine and oxycodone (for sale), were
insufficient to provide for the estimated medical, scientific, research
and industrial needs of the United States, for export requirements and
for the establishment and maintenance of reserve stocks.
The DEA has reviewed the involved companies' 1994 year-end
inventories, their initial 1995 manufacturing quotas, 1995 export
requirements and their actual and projected 1995 sales. Based on this
data, the DEA has adjusted the revised 1995 aggregate production quotas
for amphetamine, diphenoxylate, fentanyl, hydromorphone, methadone,
methadone intermediate (for conversion), morphine and oxycodone (for
sale) to meet the estimated medical, scientific, research and
industrial needs of the United States.
Regarding hydrocodone and methylphenidate, the DEA has decided that
no adjustments are necessary to meet the 1995 estimated medical,
scientific, research and industrial needs of the United States.
The Office of Management and Budget has determined that notices of
aggregate production quotas are not subject to centralized review under
Executive Order 12866. This action has been analyzed in accordance with
the principles and criteria contained in Executive Order 12612, and it
has been determined that this matter does not have sufficient
Federalism implications to warrant the preparation of a Federalism
Assessment.
The Deputy Administrator hereby certifies that this action will
have no significant impact upon small entities whose interests must be
considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq.
The establishment of aggregate production quotas for Schedules I and II
controlled substances is mandated by law and by international treaty
obligations. While aggregate production quotas are of primary
importance to large manufacturers, their
[[Page 35051]]
impact upon small entities is neither negative nor beneficial.
Accordingly, the Deputy Administrator has determined that this action
does not required a regulatory flexibility analysis.
Therefore, under the authority vested in the Attorney General by
Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826),
delegated to the Administrator by Section 0.100 of Title 28 of the Code
of Federal Regulations, and redelegated to the Deputy Administrator of
the DEA by Section 0.104 of Title 28 of the Code of Federal
Regulations, the Deputy Administrator hereby orders that the 1995
revised aggregate production quotas, expressed in grams of anhydrous
acid or base, be established as follows:
------------------------------------------------------------------------
Established
Basic class revised 1995
quotas
------------------------------------------------------------------------
Schedule I:
Acetylmethadol.................................... 7
Alphacetylmethadol................................ 5
Aminorex.......................................... 7
Bufotenine........................................ 10
Cathinone......................................... 9
Difenoxin......................................... 14,000
Dihydromorphine................................... 5
2,5-Dimethoxyamphetamine.......................... 15,650,000
Dimethoxyamphetamine.............................. 7
Ethylamine analog of Phencyclidine................ 5
N-Ethylamphetamine................................ 9
Lysergic acid diethylamide........................ 56
Mescaline......................................... 7
Methaqualone...................................... 7
Methcathinone..................................... 14
4-Methoxyamphetamine.............................. 17
4-Methylaminorex.................................. 2
3,4-Methylenedioxyamphetamine..................... 17
3,4-Methylenedioxy-N-ethylamphetamine............. 27
3,4-Methylenedioxymethamphetamine................. 17
3-Methylfentanyl.................................. 14
Normethadone...................................... 5
Normorphine....................................... 7
Tetrahydrocannabinols............................. 35,000
Thiophene Analog of Phencyclidine................. 10
Schedule II:
Alfentanil........................................ 7,000
Amobarbital....................................... 15
Amphetamine....................................... 1,226,000
Cocaine........................................... 550,000
Codeine (for sale)................................ 67,312,000
Codeine (for conversion).......................... 16,181,000
Desoxyephedrine................................... 1,154,000
------------------------------------------------------------------------
(1,138,000 grams of levo-desoxyephedrine for use in a non-controlled,
non-prescription product and 16,000 grams for methamphetamine)
------------------------------------------------------------------------
Dextropropoxyphene................................ 124,012,000
Dihydrocodeine.................................... 100,000
Diphenoxylate..................................... 965,000
Ecogonine (for conversion)........................ 650,000
Ethylmorphine..................................... 10
Fentanyl.......................................... 114,200
Hydrocodone....................................... 8,474,000
Hydromorphone..................................... 435,500
Isomethadone...................................... 10
Levo-alpha-acetylmethadol......................... 200,000
Levorphanol....................................... 8,000
Meperidine........................................ 9,521,000
Methadone......................................... 4,388,000
Methadone (for conv).............................. 364,000
Methadone Intermediate (for sale)................. 0
Methadone Int. (for conv)......................... 5,533,000
Methylphenidate................................... 10,410,000
Morphine (for sale)............................... 11,145,000
Morphine (for conv)............................... 78,105,000
Noroxymorphone (for sale)......................... 21,000
Noroxymorphone (for conv)......................... 3,500,000
Opium............................................. 1,304,000
Oxycodone (for sale).............................. 4,794,000
Oxycodone (for conv).............................. 25,500
Oxymorphone....................................... 10,200
Pentobarbital..................................... 15,706,000
[[Page 35052]]
Phencyclidine..................................... 72
Phenylacetone (for conv).......................... 3,528,000
1-Phenylcyclohexylamine........................... 10
1-Piperidinocyclohexanecarbonitrile............... 10
Secobarbital...................................... 322,000
Sufentanil........................................ 1,600
Thebaine.......................................... 9,383,000
------------------------------------------------------------------------
Dated: June 26, 1995.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 95-16321 Filed 7-3-95; 8:45 am]
BILLING CODE 4410-09-M